Skip to main content

Table 3 Diagnostic performance of preoperative CE-MRI in different histologic and biologic tumor subtypes

From: Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)

Percentage (95% CI)

Ductal

Lobular

Others

P value*

HR+

HR-

P value*

pCR rate:

33%

12%

10%

18%

40%

Sensitivity

76%

(64–86%)

0%

(0–76%)

100%

(11–100%)

0.120

77%

(55–92%)

73%

(59–85%)

0.777

Specificity

70%

(62–78%)

67%

(35–85%)

58%

(32–77%)

0.488

65%

(55–76%)

69%

(57–79%)

0.631

PPV

56%

(45–66%)

0%

(0–47%)

20%

(2–51%)

0.003

33%

(20–47%)

61%

(47–73%)

0.004

NPV

85%

(77–91%)

83%

(46–95%)

100%

(65–100%)

0.536

93%

(84–97%)

80%

(68–89%)

0.040

Accuracy

72%

(65–78%)

59%

(33–81%)

62%

(37–81%)

0.024

67%

(58–75%)

71%

(62–78%)

0.004

  1. CE-MRI contrast-enhanced magnetic resonance imaging, pCR pathologic complete response, PPV positive predictive value, NPV negative predictive value
  2. *Fisher’s exact test for all subgroups